PE20140216A1 - Formulaciones inmunosupresoras - Google Patents

Formulaciones inmunosupresoras

Info

Publication number
PE20140216A1
PE20140216A1 PE2013001522A PE2013001522A PE20140216A1 PE 20140216 A1 PE20140216 A1 PE 20140216A1 PE 2013001522 A PE2013001522 A PE 2013001522A PE 2013001522 A PE2013001522 A PE 2013001522A PE 20140216 A1 PE20140216 A1 PE 20140216A1
Authority
PE
Peru
Prior art keywords
alkylene
aryl
ethyl
alkyl
composition
Prior art date
Application number
PE2013001522A
Other languages
English (en)
Inventor
Philippe Bouillot
Emeric Reynaud
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44022942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140216(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20140216A1 publication Critical patent/PE20140216A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FASE SOLIDA QUE COMPRENDE: A) UN INGREDIENTE FARMACEUTICO ACTIVO (API) QUE ES MODULADOR DEL RECEPTOR PARA ESFINGOSINA-1-FOSFATO (S1P) TAL COMO LOS COMPUESTOS DE FORMULA A1 O A2 EN DONDE A ES COOR5, OPO(OR5)2, ENTRE OTROS, EN DONDE R5 ES H O UN GRUPO FORMADOR DE ESTER; W ES UN ENLACE, ALQUILENO(C1-C3) O ALQUENILENO(C2-C3); Y ES ARILO(C6-C10), ALQUILO(C1-C6), ENTRE OTROS; Z ES AZETIDINA, PIRROLIDINA, PIPERIDINA, ENTRE OTROS; R1 ES ARILO(C6-C10), HETEROARILO, ENTRE OTROS; R2 ES H, ALQUILO(C1-C6), ALQUENILO(C2-C6), ENTRE OTROS; R3 Y R4 SON CADA UNO H, HALOGENO, OH, ENTRE OTROS; SIENDO UN COMPUESTO PREFERIDO EL ACIDO 1-{4-[1-(4-CICLOHEXIL-3-TRIFLUORO-METIL-BENCILOXI-IMINO)-ETIL]-2-ETIL-BENCIL}-AZETIDIN-3-CARBOXILICO O UNA SAL DE HEMI-FUMARATO DEL MISMO; Y B) EXCIPIENTES TALES COMO UN DESECANTE. DICHA COMPOSICION SE RECUBRE CON UNA BARRERA A LA HUMEDAD Y TIENE UNA CRISTALINIDAD DEL 80 POR CIENTO, SIENDO UTIL EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES TALES COMO ARTRITIS REUMATOIDE, LUPUS ERITEMATOSO SISTEMICO, ESCLEROSIS MULTIPLE
PE2013001522A 2011-01-07 2012-01-05 Formulaciones inmunosupresoras PE20140216A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11150431 2011-01-07

Publications (1)

Publication Number Publication Date
PE20140216A1 true PE20140216A1 (es) 2014-03-01

Family

ID=44022942

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001522A PE20140216A1 (es) 2011-01-07 2012-01-05 Formulaciones inmunosupresoras

Country Status (35)

Country Link
US (3) US20130273161A1 (es)
EP (2) EP2661261B1 (es)
JP (2) JP6111202B2 (es)
KR (2) KR101951966B1 (es)
CN (1) CN103458877B (es)
AR (2) AR084801A1 (es)
AU (1) AU2012204835B2 (es)
BR (1) BR112013017302B1 (es)
CA (1) CA2823616C (es)
CL (1) CL2013001979A1 (es)
CO (1) CO6761402A2 (es)
CY (1) CY1122182T1 (es)
DK (1) DK2661261T3 (es)
EA (1) EA026144B9 (es)
EC (1) ECSP13012812A (es)
ES (1) ES2751920T3 (es)
GT (1) GT201300178A (es)
HR (1) HRP20191842T1 (es)
HU (1) HUE045612T2 (es)
IL (1) IL227094B (es)
JO (1) JO3619B1 (es)
LT (1) LT2661261T (es)
MA (1) MA34897B1 (es)
MX (2) MX357304B (es)
MY (1) MY161162A (es)
PE (1) PE20140216A1 (es)
PL (1) PL2661261T3 (es)
PT (1) PT2661261T (es)
SG (1) SG191286A1 (es)
SI (1) SI2661261T1 (es)
TN (1) TN2013000257A1 (es)
TW (2) TWI583380B (es)
UA (1) UA114283C2 (es)
WO (1) WO2012093161A1 (es)
ZA (1) ZA201304465B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2823616C (en) 2011-01-07 2019-01-29 Novartis Ag Immunosuppressant formulations
SG11201607894RA (en) * 2014-04-10 2016-10-28 Novartis Ag S1p modulator immediate release dosage regimen
SI3129006T1 (sl) * 2014-04-10 2021-08-31 Novartis Ag Formulacija imunosupresivov
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
WO2017006855A1 (ja) 2015-07-03 2017-01-12 アステラス製薬株式会社 安定な経口投与用医薬組成物
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
AU2018341136A1 (en) 2017-09-27 2020-03-12 Novartis Ag Parenteral formulation comprising siponimod
RU2020114751A (ru) 2017-09-29 2021-10-29 Новартис Аг Схема введения доз сипонимода
MX2020007268A (es) 2017-09-29 2020-08-17 Novartis Ag Regimen de dosificacion de siponimod.
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
WO2021214717A1 (en) 2020-04-23 2021-10-28 Novartis Ag Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome
WO2023172508A1 (en) * 2022-03-09 2023-09-14 Isp Investments Llc Co-processed excipient composition
WO2024126409A1 (en) 2022-12-12 2024-06-20 Synthon B.V. Pharmaceutical composition of siponimod

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3872113A (en) 1972-05-30 1975-03-18 Endo Lab Hydroxy- and acetoxy-phthalaldehydric acid, O-(substituted) oximes
ES2126658T3 (es) 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
EP0771339B1 (en) 1994-07-12 2003-10-15 BPSI Holdings, Inc. Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
CZ285953B6 (cs) 1995-12-28 1999-12-15 Yoshitomi Pharmaceutical Industries, Ltd. Vnější přípravek pro topické podání
MY121470A (en) 1999-05-03 2006-01-28 Ranbaxy Lab Ltd Stable solid pharmaceutical compositions containing enalapril maleate
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
AR041786A1 (es) 2002-03-15 2005-06-01 Novartis Ag Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento
SI1505959T1 (sl) 2002-05-16 2009-04-30 Novartis Ag Uporaba vezavnih sredstev EDG receptorjev pri raku
CA2504797C (en) * 2002-11-07 2011-08-23 Taisho Pharmaceutical Co., Ltd. Base for oral composition and the oral composition
CN1767819B (zh) 2003-04-08 2010-07-28 诺瓦提斯公司 包含s1p受体激动剂和糖醇的固体药物组合物
CL2004001120A1 (es) 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
BRPI0410746A (pt) 2003-05-19 2006-06-27 Irm Llc compostos e composições imunossupressoras
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US20050090520A1 (en) 2003-09-12 2005-04-28 Per Lindquist Treatment of disease or injury of the nervous system with FTY720
BRPI0415953B8 (pt) 2003-10-29 2021-05-25 Wyeth Corp formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
MXPA06012663A (es) 2004-05-03 2007-01-16 Novartis Ag Combinaciones que comprenden un agonista del receptor s1p y un inhibidor de quinasa jak3.
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP1819326B1 (en) 2004-11-29 2014-07-02 Novartis AG Dosage regimen of an s1p receptor agonist
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
RU2296999C2 (ru) 2005-03-09 2007-04-10 Алексей Арнольдович Корженевский Способ выявления критериев для проведения адекватной иммунотерапии гнойно-септических заболеваний
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
JP2009507047A (ja) 2005-09-09 2009-02-19 ラボファーム インコーポレイテッド 持続性薬物放出組成物
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008072056A1 (en) 2006-12-14 2008-06-19 Pfizer Limited Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation
DE102007019417A1 (de) 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
US20100093672A1 (en) 2007-05-04 2010-04-15 Yves-Alain Barde Use of s1p receptor modulator
EP3120833A1 (en) * 2007-10-12 2017-01-25 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
NZ588505A (en) 2008-03-17 2012-09-28 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one
KR20180017232A (ko) 2008-06-20 2018-02-20 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
BRPI0916232A2 (pt) 2008-07-23 2017-08-29 Novartis Ag Moduladores do receptor de esfingosina-1-fosfato e seu uso para tratar inflamação muscular
PT2326325E (pt) 2008-08-18 2015-02-05 Novartis Ag Derivado de azetidina para o tratamento de neuropatias periféricas
CN103204794A (zh) 2008-12-18 2013-07-17 诺瓦提斯公司 新的盐
KR20110112352A (ko) 2008-12-18 2011-10-12 노파르티스 아게 1-（4-｛ｌ-［（ｅ）-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노］-에틸｝-2-에틸-벤질）-아제티딘-3-카르복실산의 신규한 다형체 형태
PT2379497E (pt) 2008-12-18 2013-11-29 Novartis Ag Sal hemifumarato do ácido 1-(4-{1-[(e)-4-ciclo-hexil-3- trifluorometil-benziloxi-imino]-etil}-2-etil-benzil)- azetidina-3-carboxílico
JP2012512676A (ja) 2008-12-19 2012-06-07 ノバルティス アーゲー 吸入器用マウスピース
JP5657565B2 (ja) 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
EP2907511A1 (en) 2008-12-22 2015-08-19 Novartis AG Dosage regimen for a s1p receptor agonist
CA2773330C (en) 2009-09-29 2021-11-02 Novartis Ag Dosage regimen of an s1p receptor modulator
CA2823616C (en) 2011-01-07 2019-01-29 Novartis Ag Immunosuppressant formulations
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
CA3149287A1 (en) 2013-04-04 2014-10-09 Novartis Ag Identifying patient response to s1p receptor modulator administration
SI3129006T1 (sl) 2014-04-10 2021-08-31 Novartis Ag Formulacija imunosupresivov

Also Published As

Publication number Publication date
MX371290B (es) 2020-01-24
EA201391018A1 (ru) 2013-11-29
WO2012093161A1 (en) 2012-07-12
MA34897B1 (fr) 2014-02-01
ECSP13012812A (es) 2013-09-30
EP2661261A1 (en) 2013-11-13
CN103458877B (zh) 2016-06-08
CY1122182T1 (el) 2020-11-25
BR112013017302B1 (pt) 2021-12-07
AU2012204835A1 (en) 2013-08-01
AR084801A1 (es) 2013-06-26
SI2661261T1 (sl) 2019-11-29
JP6111202B2 (ja) 2017-04-05
LT2661261T (lt) 2019-10-25
NZ612420A (en) 2015-05-29
KR101951966B1 (ko) 2019-02-25
KR102166885B1 (ko) 2020-10-19
GT201300178A (es) 2014-12-30
US12071402B2 (en) 2024-08-27
IL227094B (en) 2019-03-31
JP2017141248A (ja) 2017-08-17
EP2661261B1 (en) 2019-07-31
CL2013001979A1 (es) 2013-11-22
CA2823616A1 (en) 2012-07-12
EP3590507A1 (en) 2020-01-08
CA2823616C (en) 2019-01-29
AU2012204835B2 (en) 2015-07-09
US20220064110A1 (en) 2022-03-03
ZA201304465B (en) 2014-02-26
KR20190025727A (ko) 2019-03-11
CN103458877A (zh) 2013-12-18
JP6324569B2 (ja) 2018-05-16
MX357304B (es) 2018-07-04
KR20140037815A (ko) 2014-03-27
EA026144B1 (ru) 2017-03-31
ES2751920T3 (es) 2020-04-02
DK2661261T3 (da) 2019-10-21
BR112013017302A2 (pt) 2016-10-25
AR124662A2 (es) 2023-04-19
JO3619B1 (ar) 2020-08-27
CO6761402A2 (es) 2013-09-30
HUE045612T2 (hu) 2020-01-28
TW201609092A (zh) 2016-03-16
US20200199069A1 (en) 2020-06-25
PT2661261T (pt) 2019-10-25
TN2013000257A1 (en) 2014-11-10
TWI583380B (zh) 2017-05-21
PL2661261T3 (pl) 2020-01-31
TW201249438A (en) 2012-12-16
HRP20191842T1 (hr) 2019-12-27
MX2013007909A (es) 2013-08-29
EA026144B9 (ru) 2021-10-26
US20130273161A1 (en) 2013-10-17
JP2014501770A (ja) 2014-01-23
MY161162A (en) 2017-04-14
TWI610672B (zh) 2018-01-11
SG191286A1 (en) 2013-07-31
UA114283C2 (uk) 2017-05-25

Similar Documents

Publication Publication Date Title
PE20140216A1 (es) Formulaciones inmunosupresoras
PH12017501294A1 (en) Compounds, compositions and methods useful for cholesterol mobilisation
CY1123370T1 (el) Σταθερη ενεσιμη φαρμακευτικη συνθεση ανταγωνιστη υποδοχεα νευροκινινης 1 και μεθοδος παρασκευης αυτης
PH12016500777A1 (en) Compositions and methods for modulating farnesoid x receptors
PE20170502A1 (es) ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6
IN2014CN03803A (es)
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
EA201891018A1 (ru) Липиды и липидные композиции для доставки активных агентов
EA201492281A1 (ru) Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
IN2014MN02598A (es)
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
PH12015501752B1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
MX2015005858A (es) Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
MX358499B (es) Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40).
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
PE20091419A1 (es) Derivados acidos de carboxicicloalquilamino como moduladores de los receptores de esfingosina-1-fosfato (s1p)
MX2015005720A (es) Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
EA201391524A1 (ru) Производные гликозида и их применение
TN2013000471A1 (en) Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
UY33279A (es) Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2
IL206739A (en) An injectable drug containing silitol as an active substance

Legal Events

Date Code Title Description
FG Grant, registration